Tagged with Investment

investment Besides protecting the health of Mexicans, COFEPRIS today offers an important value-added to the investment community: predictability. The organization’s commissioner shares the astonishing results of his last three years of tenure, undertaken with the priority of improving access of the population to a well-supplied drug market and making the Mexican…

manufacturing Merck is getting “Fit for 2018”. Pedro Galvis, the company’s managing director for Mexico, discusses how the company’s transformation program, implemented in 2012, is ensuring future growth and how Mexico’s manufacturing cost competitiveness has driven further investment in production capacities. What is the major challenge that R&D-driven multinational companies face…

investment Johannes Hauser, managing director of the German-Mexican Chamber of Commerce explains the role of the chamber in Mexico and encourages small and medium-sized companies in Germany to consider the country as a destination to expand their business. The German-Mexican Chamber of Commerce dates back to 1929. What are the Chamber’s…

manufacturing The CEO of one of Algeria’s most successful pharmaceutical firms describes how El Kendi became the first foreign firm to be established in Algeria without having a mother company abroad. He also lifts the lid on the secrets behind the firms extraordinary track record for speed in securing product registration and approval on…

Parexel Pilar Rivas, associate director of global contract research organization Parexel’s Spanish affiliate, discusses cultural differences across Spain and their impact on clinical trials, as well as the world-class infrastructure that allows CROs in Spain to perform high-quality research.   Do you feel that supporting clinical research is a priority for the…

association The American Chamber of Commerce in Korea (Amcham Korea) was established in 1953 and has a long history in developing bilateral economic and trade relations between the US and Korea. Amy Jackson, president of the Chamber, discusses the implementation and effects of the Korea-US Free Trade Agreement (FTA) and the contributions…

innovation Dr. Jung Yun-Taek, head researcher of the pharmaceutical division at the Korea Health Industry Development Institute (KHIDI), discusses the real potential that Korean pharmaceutical companies offer to the rest of the world for disruptive and incremental innovation.   What are the current trends in Korea’s pharmaceutical industry? The global market…

API Indian companies are increasingly interested in tapping into the alluring Mexican and Latin American pharmaceutical markets. The general manager of the API and drug producer discusses the vision behind the establishment of operations in Mexico, the company’s achievements so far and its future plans to consolidate local manufacturing and launch…

university The executive director of Latin America’s largest plasma fractionation plant, a publicly-funded laboratory within the 400 year old National University of Cordoba, discusses the organization’s social responsibility as a provider and leader for plasma derived therapies in the region, and their exciting pipeline of innovative biotech products.     How does Hemoderivados’s…

innovation The general manager of BI Algeria discusses how Algeria could benefit from participating in international clinical trials and describes how his company is adapting its offering to mirror the changing health profile of the nation which is currently undergoing a transition from infectious and transmissible disease to chronic and lifestyle illnesses.…

research The director general for Scientific Research and Technological Development discusses the authorities’ efforts to incentivize R&D and to harmonize sectoral development strategies to achieve national economic growth outcomes. He also identifies bottlenecks in the human capital base and the importance of raising the intellectual and scientific level of the local…

Deloitte In the second part of this interview, the managing partner of Deloitte Algeria sheds light on opportunity and risk in the Algerian pharma market. He explains the distorting effect of strict joint venture rules and outlines the many challenges in navigating Algeria’s regulatory and legal frameworks while at the same time…